Drug Trial Radar · NCT05047523
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
40
Actual
Start
Sep 13, 2021
Primary completion
Jun 26, 2023
Study completion Jun 26, 2023
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).
Conditions
- Wilson Disease
Interventions
ALXN1840Drug
Administered as an oral tablet.
Standard of CareDrug
Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline to Week 48 in Non-ceruloplasmin-bound Copper in PlasmaTime frame: Baseline, Week 48
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Parkville, Australia
Research Site
South Brisbane, Australia
Research Site
Lille, France
Research Site
Toulouse, France
Research Site
Hanover, Germany
Research Site
Tübingen, Germany
Research Site
Kumamoto, Japan
Research Site
Kurume-shi, Japan
Research Site
Meguro-ku, Japan
Research Site
Sapporo, Japan
Research Site
Warsaw, Poland
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Esplugues de Llobregat, Spain
Research Site
Las Palmas de Gran Canaria, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Pamplona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.